AICD indications (patient selection): Past, present and future

Research output: Contribution to journalArticle

Abstract

During the course of a seven year implant experience with the Automatic Implantable Cardioverter-Defibrillator (AICD) now extending to well over 3,700 implantees, several functional advances have been made in the pulse generators, and criteria for implantation were successively broadened. Survival statistics have been excellent with 1-year arrhythmic survival over 98%, and total survival from all causes of death in excess of 60% at 5 years. Still, only relatively few of the patients who could possibly be helped by this device actually receive one. Reasons for this are probably complex but include, among other things, the relative newness of electrophysiology as a subspecialty, and a lack of appreciation by the general medical public in regard to this particular treatment modality. Small increases in referral patterns thus can have the potential to produce marked increases in the utilization of AICDs. Additionally, other high risk populations appear to be ready for inclusion into AICD therapeutic trials, and techniques also appear at hand to examine presumably healthy populations so as to predict those subject to suffer eventual sudden cardiac arrest. Under such circumstances, the ultimate impact of AICD therapy can hardly be imagined.

Original languageEnglish (US)
Pages (from-to)2064-2070
Number of pages7
JournalPACE - Pacing and Clinical Electrophysiology
Volume11
Issue number11 II
StatePublished - 1988

Fingerprint

Implantable Defibrillators
Patient Selection
Survival
Electrophysiology
Sudden Cardiac Death
Population
Cause of Death
Therapeutics
Referral and Consultation
Hand
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

AICD indications (patient selection) : Past, present and future. / Mower, Morton Maimon; Nisam, S.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 11, No. 11 II, 1988, p. 2064-2070.

Research output: Contribution to journalArticle

@article{169ae74a61e548f7b7435fe34d111635,
title = "AICD indications (patient selection): Past, present and future",
abstract = "During the course of a seven year implant experience with the Automatic Implantable Cardioverter-Defibrillator (AICD) now extending to well over 3,700 implantees, several functional advances have been made in the pulse generators, and criteria for implantation were successively broadened. Survival statistics have been excellent with 1-year arrhythmic survival over 98{\%}, and total survival from all causes of death in excess of 60{\%} at 5 years. Still, only relatively few of the patients who could possibly be helped by this device actually receive one. Reasons for this are probably complex but include, among other things, the relative newness of electrophysiology as a subspecialty, and a lack of appreciation by the general medical public in regard to this particular treatment modality. Small increases in referral patterns thus can have the potential to produce marked increases in the utilization of AICDs. Additionally, other high risk populations appear to be ready for inclusion into AICD therapeutic trials, and techniques also appear at hand to examine presumably healthy populations so as to predict those subject to suffer eventual sudden cardiac arrest. Under such circumstances, the ultimate impact of AICD therapy can hardly be imagined.",
author = "Mower, {Morton Maimon} and S. Nisam",
year = "1988",
language = "English (US)",
volume = "11",
pages = "2064--2070",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "11 II",

}

TY - JOUR

T1 - AICD indications (patient selection)

T2 - Past, present and future

AU - Mower, Morton Maimon

AU - Nisam, S.

PY - 1988

Y1 - 1988

N2 - During the course of a seven year implant experience with the Automatic Implantable Cardioverter-Defibrillator (AICD) now extending to well over 3,700 implantees, several functional advances have been made in the pulse generators, and criteria for implantation were successively broadened. Survival statistics have been excellent with 1-year arrhythmic survival over 98%, and total survival from all causes of death in excess of 60% at 5 years. Still, only relatively few of the patients who could possibly be helped by this device actually receive one. Reasons for this are probably complex but include, among other things, the relative newness of electrophysiology as a subspecialty, and a lack of appreciation by the general medical public in regard to this particular treatment modality. Small increases in referral patterns thus can have the potential to produce marked increases in the utilization of AICDs. Additionally, other high risk populations appear to be ready for inclusion into AICD therapeutic trials, and techniques also appear at hand to examine presumably healthy populations so as to predict those subject to suffer eventual sudden cardiac arrest. Under such circumstances, the ultimate impact of AICD therapy can hardly be imagined.

AB - During the course of a seven year implant experience with the Automatic Implantable Cardioverter-Defibrillator (AICD) now extending to well over 3,700 implantees, several functional advances have been made in the pulse generators, and criteria for implantation were successively broadened. Survival statistics have been excellent with 1-year arrhythmic survival over 98%, and total survival from all causes of death in excess of 60% at 5 years. Still, only relatively few of the patients who could possibly be helped by this device actually receive one. Reasons for this are probably complex but include, among other things, the relative newness of electrophysiology as a subspecialty, and a lack of appreciation by the general medical public in regard to this particular treatment modality. Small increases in referral patterns thus can have the potential to produce marked increases in the utilization of AICDs. Additionally, other high risk populations appear to be ready for inclusion into AICD therapeutic trials, and techniques also appear at hand to examine presumably healthy populations so as to predict those subject to suffer eventual sudden cardiac arrest. Under such circumstances, the ultimate impact of AICD therapy can hardly be imagined.

UR - http://www.scopus.com/inward/record.url?scp=0024234542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024234542&partnerID=8YFLogxK

M3 - Article

C2 - 2463589

AN - SCOPUS:0024234542

VL - 11

SP - 2064

EP - 2070

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 11 II

ER -